CYPH
Cypherpunk Technologies Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Cypherpunk Technologies Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Cypherpunk Technologies has 7 disclosed suppliers and 0 disclosed customers in SEC filings.
Cypherpunk Technologies Inc.
2.98
SentenceOn August 10, 2020, we entered into a collaboration agreement with Adimab, LLC (the "Adimab Agreement"), pursuant to which Adimab will conduct research programs to develop monoclonal antibodies to certain targets identified by us and provide us with an option to acquire exclusive rights to such antibodies.
CYPH 10-Kaccession 0001104659-26-028566
SentenceWe participate, through our subsidiary in Australia, in the Australian government's R&D Incentive program, such that a percentage of our eligible research and development expenses are reimbursed by the Australian government as a refundable tax offset and such incentives are reflected as other income.
CYPH 10-Kaccession 0001104659-26-028566
SentenceWe hold digital assets in the form of Zcash with Gemini, a third-party custodian ("Gemini").
CYPH 10-Kaccession 0001104659-26-028566
SentenceIn patients with high circulating DKK1 plasma levels (upper quartile as measured by the SomaLogic SomaScan platform, n=44), the sirexatamab experimental arm has improved ORR, by both investigator-assessment ("IA") and blinded independent central review ("BICR"), PFS, and OS compared to the control arm:
CYPH 10-Kaccession 0001104659-26-028566
SentencePublished data, including from The Cancer Genome Atlas ("TCGA") and real world evidence from our collaboration with Tempus, indicate that DKK1 levels are significantly higher or have an important high DKK1 population in many cancers, including esophagogastric cancer, non-small cell lung cancer, endometrial cancer, CRC, and pancreatic cancer.
CYPH 10-Kaccession 0001104659-26-028566
—
Linked news
Expected move
No implied move.